KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors

S. Hong, David; Fakih, Marwan; H. Strickler, John; Desai, Jayesh; A. Durm, Gregory; I. Shapiro, Geoffrey; S. Falchook, Gerald; Price, Timothy; G. Sacher, Adrian; S. Denlinger, Crystal; Bang, Yung‐Jue; K. Dy, Grace; C. Krauss, John; Kuboki, Yasutoshi; Kuo, James; L. Coveler, Andrew; Park, Keunchil; Won Kim, Tae; Barlési, Fabrice; N. Münster, Pamela; S. Ramalingam, Suresh; F. Burns, Timothy; Meric‐Bernstam, Funda; Henary, Haby; Ngang, Jude; Ngarmchamnanrith, Gataree; Myung Kim, June; E. Houk, Brett; Canon, Jude; Russell Lipford, J.; Friberg, Gregory; Lito, Piro; Govindan, Ramaswamy; T. Li, Bob

doi:10.1056/nejmoa1917239

Public

KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

Published in New England Journal of Medicine • Sep 20, 2020

Authors:

David S. Hong

Marwan Fakih

John H. Strickler

Abstract

BACKGROUND: . METHODS: p.G12C mutation. Patients received sotorasib orally once daily. The primary end point was safety. Key secondary end points were pharmacokinetics and objective response, as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. RESULTS: A tota...

Subject

KRAS

Radiochemistry

Nuclear medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!